Memorial Sloan Kettering hematologic oncologist Mark Geyer

Mark B. Geyer, MD

Leukemia Specialist & Cellular Therapist

My Role at MSK

Areas of Expertise

My Specialties

  • Adult Acute and Chronic Leukemias
  • Acute Lymphoblastic Leukemia (ALL)
  • Chronic Lymphocytic Leukemia (CLL)

Request an Appointment

Our Care Advisors can answer many of your questions. They will connect you with the best healthcare provider for your needs.
English
Share

About Me

What I Do at MSK
  • Adolescent and Young Adult Program Leader, Leukemia Service
  • Adult Lymphoblastic Leukemia Program Leader, Leukemia Service
  • Chair, Quality Assessment, Cellular Therapy Service
Get To Know Me

I am a hematologist and medical oncologist who specializes in caring for people with leukemia. I am a member of the Leukemia Service and Cellular Therapy Service at Memorial Sloan Kettering Cancer Center (MSK). I am committed to providing personalized, compassionate care for our patients and their families.

Read more

I often meet patients and their families and caregivers during a very challenging and emotionally charged period in their lives. I value the strong partnerships that our clinical team forms with our patients and their caregivers through both illness and wellness. I want us to make important decisions about care together.

Caring for and adolescent and young adult (AYA) patients with leukemia is particularly important to me. At the time of their diagnosis, many AYAs with leukemia are continuing education or training, starting their careers, and building relationships and families. In my role as AYA Program Leader for the Leukemia Service, I work with other providers in the Lisa and Scott Stuart Center for Adolescent and Young Adult Cancers to meet the unique medical, social, and emotional needs of our AYA patients and their families. These efforts include ensuring our AYA patients have access to well-designed clinical trials run by both the Pediatric and Adult Leukemia Services.

As a researcher, I want to improve the way we treat blood cancers. My research focuses on learning about and developing safe and effective therapies for acute lymphoblastic leukemia and other blood cancers. I have a strong interest, for example, in using the power of the immune system to fight blood cancers more effectively. This treatment approach is called immunotherapy. I am able to prescribe commercially available chimeric antigen receptor (CAR) T cell therapies for people with leukemia or lymphoma. I am also leading several clinical trials investigating new CAR T cell therapies and ways to make these treatments safer and more effective. CAR T cell therapy has a different set of challenges compared with traditional chemotherapy. Because of the skill and experience of the nurses and doctors at MSK, we can deliver the newest treatments in the safest possible manner.

When I meet with patients, my goal is for them to leave the appointment feeling informed and empowered. I want them to know that they are in good hands. I listen carefully to their perspective and address their concerns. I also explain the range of options available to us, outline the advantages and disadvantages of each, and offer my recommendations. I often remind my patients and their families that we never stop caring for them. Our entire team of experts will be there to support and guide them through all the stages of their journey.

Outside of MSK, I enjoy staying active, including distance running, listening to live music, including local artists, discovering new places in New York City and around the world, and spending time with my fiancé. It is always wonderful to learn how my patients like to spend their time as well, so our team can support them as best as possible.

My Role at MSK

A leukemia specialist is a doctor with special training in diagnosing and treating leukemia.

A cellular therapy specialist is a doctor with special training in using cell therapies to treat health conditions such as cancer. Therapies can include chimeric antigen receptor (CAR) T cell therapy.

Areas of Expertise

My Specialties

  • Adult Acute and Chronic Leukemias
  • Acute Lymphoblastic Leukemia (ALL)
  • Chronic Lymphocytic Leukemia (CLL)
  • Chronic Myeloid Leukemia (CML)
  • Hairy Cell Leukemia
  • Lymphoproliferative Disorders
  • Cellular Immunotherapy
Education & Honors

Education

  • MD, Columbia University College of Physicians and Surgeons

Residencies

  • Internal Medicine – Massachusetts General Hospital

Awards and Honors

  • Memorial Sloan Kettering Department of Medicine Teaching Excellence Award (2021-2022)
  • Memorial Sloan Kettering Hematology Attending Teaching Award (2020-2021)
  • American Society of Hematology Scholar Award (2018-2020)
  • Lymphoma Research Foundation Postdoctoral Fellowship Grant (2017-2019)
  • Abstract Achievement Award, American Society of Hematology (2016)
  • Conquer Cancer Foundation Merit Award, American Society of Clinical Oncology (2016)

Fellowships

  • Hematology/Medical Oncology – Memorial Sloan Kettering Cancer Center

Board Certifications

  • Internal Medicine
  • Hematology
  • Medical Oncology

Insurance Information

Understanding your insurance options is an important part of managing your cancer care. We have relationships with many common healthcare providers and plans.

Aetna

In Network Coverage Type
HMO, EPO PPO, POS, Transplant

Aetna Medicare Advantage (MTA retirees only)

In Network Coverage Type
PPO

Blue Cross Blue Shield Federal Employee Program

In Network Coverage Type
HMO, PPO

Blue Cross Blue Shield New York

In Network Coverage Type
PPO, POS, EPO, HMO

Blue Cross Blue Shield states outside of NY/NJ

In Network Coverage Type
HMO, EPO PPO, POS

Blue Cross Health Plus

In Network Coverage Type
HMO

Carrum Health

In Network Coverage Type
Supplemental

Cigna

In Network Coverage Type
PPO, POS, HMO

MSK has a tentative agreement with Cigna to continue coverage in 2024.

Connecticare

In Network Coverage Type
POS, EPO, HMO

Emblem

In Network Coverage Type
PPO, POS, EPO, HMO

Emblem Essential

In Network Coverage Type
HMO

Emblem Medicare Advantage

In Network Coverage Type
PPO, HMO

Empire Blue Cross Medicare Advantage

In Network Coverage Type
PPO, HMO, DSN

Empire Essential

In Network Coverage Type
HMO

Empire Plan / NYSHIP (Blue Cross/UnitedHealthcare split plan)

In Network Coverage Type
PPO

Fidelis

In Network Coverage Type
HMO, EPO

Fidelis Managed Medicaid & HARP

In Network Coverage Type
HMO

Fidelis Medicare Advantage

In Network Coverage Type
HMO

First Health

In Network Coverage Type
PPO

Healthfirst

In Network Coverage Type
EPO, HMO, PPO, POS

Healthfirst Managed Medicaid

In Network Coverage Type
HMO

Healthfirst Medicare Advantage

In Network Coverage Type
HMO, PPO

Healthsmart

In Network Coverage Type
PPO EPO

Horizon Blue Cross Blue Shield New Jersey (HMO)

In Network Coverage Type
HMO

Horizon Blue Cross Blue Shield New Jersey (PPO)

In Network Coverage Type
PPO

Horizon Blue Cross Blue Shield New Jersey Omnia Tier I (EPO)

In Network Coverage Type
EPO

Horizon Blue Cross Blue Shield New Jersey Omnia Tier II (EPO)

In Network Coverage Type
EPO

Horizon Medicare Advantage

In Network Coverage Type
PPO, HMO

Husky CT Medicaid

In Network Coverage Type
State Government

Magnacare

In Network Coverage Type
PPO, POS, EPO

Straight NJ Medicaid

In Network Coverage Type
State Government

Straight NY Medicaid

In Network Coverage Type
State Government

Medicare Part A&B (traditional Medicare)

In Network Coverage Type
Federal Government

Multiplan/Beech Street/PHCS

In Network Coverage Type
Supplemental

MVP

In Network Coverage Type
PPO/OAP

Non-Participating Plans with Out of Network Benefits

In Network Coverage Type
PPO, POS, EPO, HMO

NYC Medicare Advantage Plus for City Employees

In Network Coverage Type
TBD

Oscar

In Network Coverage Type
HMO/EPO

Oxford

In Network Coverage Type
PPO, EPO

World Trade Center Health Program (WTC)

In Network Coverage Type
State Government

Qualcare

In Network Coverage Type
PPO, POS, HMO

Tricare

In Network Coverage Type
PPO, HMO

UMR

In Network Coverage Type
PPO, POS

United Healthcare

In Network Coverage Type
PPO, POS, HMO

Don't see your carrier or plan? We can help you understand your coverage.

If you don't have health insurance or are worried that your care may not be fully covered, our financial assistance programs may be able to help.

If you have questions about insurance, call us at 646-497-9176.

Make an Appointment

Current Patients

Request an appointment by logging on to MyMSK or calling your doctor’s office. If you aren’t registered for MyMSK, call 646-227-2593 for your Enrollment ID.

Contact and Location

Dr. Geyer sees patients at one location.

Looking to see a doctor at a different location? See all MSK locations.

Colleagues

Doctors at Memorial Sloan Kettering work as teams, with specialists from all different areas. This allows us to consider all your needs together, and to give you the best possible care.

See all Cellular Therapy Service doctors

See all Leukemia Service doctors

Clinical Trials

Read more
Smiling doctors in the lab
Find a Clinical Trial for You

Memorial Sloan Kettering's doctors and scientists are constantly developing new treatments for cancer. MSK is typically running hundreds of clinical trials at a given time.

You may be able to participate in a clinical trial even if you are new to MSK. Search our online directory to find trial information and see more about who can participate.

Search clinical trials

Research and Publications

Geyer MB, Shaffer BC, Bhatnagar B, Mims AS, Klein V, Dilip D, Glass JL, Lozanski G, Hassoun H, Landau H, Zhang Y, Xiao W, Roshal M, Park JH. 2023. Lenalidomide-associated B-cell ALL: clinical and pathologic correlates and sensitivity to lenalidomide withdrawal. Blood Advances. 7: 3087-3098.

Geyer MB, Ritchie EK, Rao AV, Vemuri S, Flynn J, Hsu M, Devlin SM, Roshal M, Gao Q, Shukla M, Salcedo J, Maslak P, Tallman MS, Douer D, Park JH. 2021. Pediatric-inspired chemotherapy incorporating pegaspargase is safe and results in high rates of minimal residual disease negativity in adults up to age 60 with Philadelphia chromosome-negative acute lymphoblastic leukemia. Haematologica. 106: 2086-2094.

Read more

Geyer MB, Rivière I, Sénéchal B, Wang X, Wang Y, Purdon TJ, Hsu M, Devlin SM, Halton E, van Leeuwen DG, Sadelain M, Palomba ML, Park JH, Brentjens RJ. 2019. Safety and tolerability of conditioning chemotherapy followed by CD19-targeted CAR T-cells for relapsed/refractory CLL. JCI Insight. 4(9): e122627.

King AC, Pappacena JJ, Tallman MS, Park JH, Geyer MB. 2019. Blinatumomab Administered Concurrently with Oral Tyrosine Kinase Inhibitor Therapy is a Well-Tolerated Consolidation Strategy and Eradicates Measurable Residual Disease in Adults with Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia. Leukemia Research. 79: 27-33.

Publications on PubMed

Visit PubMed for a full listing of Dr. Geyer’s journal articles. Pubmed is an online index of research papers and other articles from the US National Library of Medicine and the National Institutes of Health.

See all on PubMed

Disclosures

Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.

MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.

Mark B. Geyer discloses the following relationships and financial interests:

  • Novartis
    Professional Services and Activities
  • Sanofi-Aventis U.S. LLC
    Professional Services and Activities

If you’re a patient at MSK and would like more information about your doctor’s external relationships, please talk with your doctor.

The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.


This page and data include information for a specific MSK annual disclosure period (January 1, 2022 through disclosure submission in spring 2023). This data reflects interests that may or may not still exist. This data is updated annually.

Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at [email protected].


View all disclosures